Committed to the Healthcare Experience and Scientific Innovation
Share this
Simpson Healthcare Executives, founded by Kelly Simpson-Angelini, CEO & CSO, is a diverse scientific agency. We caught up with Danielle Gallagher to discover more about the firm who are currently celebrating their 20th year of business.
Established in 1998, Simpson Healthcare is a diverse scientific agency currently celebrating its 20th year of business. In an ever-evolving healthcare landscape, Kelly believes that providing great branded and disease education to physicians is essential to advancing the story of science that their clients need to tell. Brands of the future must be more personalised and precise as the firm prioritises the overarching goal of healthcare: helping people live better.
For the past 20 years, the firm have had the opportunity to work with heritage biopharmaceutical clients including: Pfizer, Shire, AstraZeneca, Genzyme, Merck, to name a few, having focused our innovations on supporting them in the development of new therapies. The scientific expertise and disruptive thinking methods among members of their organisation span across a broad array of many major disease categories, including respiratory, oncology, cardiovascular, immunology, rare diseases, gastrointestinal, adult vaccines, and severe asthma. The firm’s medical and strategy teams are catalysts of industry innovation as they bring to bear the larger context of healthcare for their clients, aligned in their purpose and always keeping the patient at the centre of their focus.
Discussing the steps Simpson Healthcare take when undertaking a new project to ensure that clients receive the best possible outcome, Danielle explains to us the process the team abides by.
“Here at Simpson Healthcare, we pull through the story of why our clients’ therapeutic brands matter for patients and how they will improve their lives. We dig deeper into the science of the therapies that our clients are developing and what it means for patients who could benefit the most from their therapy. At the start of a new project, our internal team will align with our client on strategic vision, project management details, and the long-term value that will be added to the healthcare industry throughout the entire therapeutic brand lifecycle. After working with our client to clearly define the problem or opportunity, we will then outline our objectives and timelines and move forward in a collaborative path.”
A few years ago, Simpson Healthcare’s leadership team, under the guidance of Kelly Simpson-Angelini CEO&CSO, revisited the mission and vision of Simpson Healthcare and transformed this into a purpose statement. This purpose is rooted in their internal core belief systems, guides their teams in every moment, and is the reason why the firm do what they do here every day at the agency. The firm’s purpose is to support their clients to share the scientific story of the disease they touch and therapies they discover for all in need. They challenge key healthcare stakeholders to think disruptively about healthcare beyond next year and into the next decade as they work to develop and deliver the therapies of the future.
Simpson Healthcare has a unique internal culture that has been designed by the founder, Kelly Simpson-Angelini to be one that is experience-driven, educational, patient-centred, and rooted in our core values. They have over 20 years of agency experience across many therapeutic areas to leverage, and also carve the path of success for their clients’ brands. Danielle goes into detail about the team and the culture within the firm, as well as how all the staff are equipped to provide the best possible service to their clients.
“At Simpson Healthcare, we realise the value in taking a step back during the decision-making process to practice mindfulness, and we examine our own thoughts, emotions, and the potential results of those decisions prior to moving forward. Our intention is always to ensure we develop and provide the right medical education to physicians that lead to the best possible outcomes for our clients and for their patient communities. In our 20th year of business alone, we are currently working to impact roughly 1/3 of both national and global populations.”
Moving forward, Kelly Simpson-Angelini believes that the firm live in a time where they must encourage both their clients and their fellow healthcare community to look beyond next year, as well as into the next decade as they pioneer the future of healthcare and uncover what patient needs are, how they may change, and how they can be most impactful in improving health outcomes. Danielle envisions what the future holds for the firm, as well as reflecting on how far Simpson Healthcare have grown throughout the years.
“The core stories of disease, diagnosis, and new therapies will continue to be new and abundant. There is a huge opportunity to continue to build knowledge and skills in organising and showcasing scientific content. We will have more brands to build, and more ways to build and explain them. A personalised and individualised approach to disease education will be something to simplify and focus on in marketing material. Most of all, we are proud to unite and support our clients, to shape the future of healthcare so that the best therapeutic treatments may be available to provide a brighter health outlook for those in need.”
